2022
DOI: 10.17116/medtech20224404151
|View full text |Cite
|
Sign up to set email alerts
|

Economic evaluation of PCSK9 inhibitors inclusion in the list of medicines for outpatient preferential drug provision («23 INNs» list) for secondary prevention of cardiovascular events

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 19 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?